Enanta Pharmaceuticals (ENTA) Cash & Current Investments (2016 - 2025)
Historic Cash & Current Investments for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q3 2025 value amounting to $188.9 million.
- Enanta Pharmaceuticals' Cash & Current Investments fell 2390.22% to $188.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $188.9 million, marking a year-over-year decrease of 2390.22%. This contributed to the annual value of $188.9 million for FY2025, which is 2390.22% down from last year.
- According to the latest figures from Q3 2025, Enanta Pharmaceuticals' Cash & Current Investments is $188.9 million, which was down 2390.22% from $204.1 million recorded in Q2 2025.
- Enanta Pharmaceuticals' 5-year Cash & Current Investments high stood at $386.6 million for Q2 2023, and its period low was $188.9 million during Q3 2025.
- In the last 5 years, Enanta Pharmaceuticals' Cash & Current Investments had a median value of $249.2 million in 2022 and averaged $264.1 million.
- In the last 5 years, Enanta Pharmaceuticals' Cash & Current Investments soared by 5720.19% in 2023 and then plummeted by 4048.27% in 2024.
- Enanta Pharmaceuticals' Cash & Current Investments (Quarter) stood at $259.1 million in 2021, then fell by 17.21% to $214.5 million in 2022, then soared by 57.2% to $337.2 million in 2023, then tumbled by 35.73% to $216.7 million in 2024, then dropped by 12.84% to $188.9 million in 2025.
- Its Cash & Current Investments was $188.9 million in Q3 2025, compared to $204.1 million in Q2 2025 and $193.4 million in Q1 2025.